Pelthos Therapeutics strikes business combination agreement with Castle Creek Biosciences

Pelthos Therapeutics has entered into a business combination agreement with Castle Creek Biosciences. Castle Creek shareholders will receive 5.2 million common shares of Pelthos in the transaction.

Detected & updated continuously · Source: Nebula